Announcing Positive Results of Saturn-2 Phase 3 Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis

Revolutionizing treatment for patients in need

Scroll To Discover
Young woman smiling. Young woman smiling. Young woman smiling.


We’re committed to delivering boundless therapeutic ingenuity

Tarsus Pharmaceuticals, Inc. is a biopharmaceutical company that embodies the values of commitment, empowerment, and teamwork. We aim to bring novel therapeutics to patients across a range of diseases with limited treatment options.


Novel therapies, beginning with the eye

For the millions of patients living with Demodex blepharitis, an FDA-approved treatment is on the horizon.

News & Media

Here is the latest from Tarsus

12/16/2022 Tarsus Added to NASDAQ Biotechnology Index
12/15/2022 Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease
11/09/2022 Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements

Contact Tarsus

Please reach out to us using the form below.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.